UAB 1984: Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Receiving Ipilimumab and/or Nivolumab

Grant

Awarded By

Total Award Amount

  • 206876.00

    • Direct Costs

  • 159135.00

    • Sponsor Award Id

    • Contributor

  • Arnab Basu   Principal Investigator  
  • Lakshminarayanan Nandagopal   Investigator  
  • Mollie Deshazo M.D.   Investigator